AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
Go back to AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress| AbbVie (NYSE: ABBV) | Delayed: 265.08 -0.13 (0.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $265.21 | 52 Week High | $68.12 | |||
| Open | $266.00 | 52 Week Low | $50.71 | |||
| Day High | $269.39 | P/E | 57.50 | |||
| Day Low | $263.59 | EPS | $4.61 | |||
| Volume | 3,469,241 | |||||
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 139.49 -2.76 (1.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.25 | 52 Week High | $58.46 | |||
| Open | $141.97 | 52 Week Low | $31.25 | |||
| Day High | $142.25 | P/E | N/A | |||
| Day Low | $139.32 | EPS | $-0.69 | |||
| Volume | 1,747,917 | |||||
